1G·

Companies with RSI below 20 🤔

$NOVO B (-1,79%)
$NVO (-2,29%)
$ZTS (+0,39%)
$CMG (+0,08%)
$GRMN (-0,57%)
$FI (+3,53%)
$TLNC34
$CELH

Found an interesting article on x:

There are over 850 stocks with a market capitalization of at least $10 billion.

Of these 850+, only 7 currently have a daily RSI below 20.

Most interesting for me $NOVO B (-1,79%) and $ZTS (+0,39%) , $CELH I will probably have to take a closer look again.

Another reason why I increased $NOVO B (-1,79%) I also topped up again yesterday.

Certainly also interesting from a trading perspective. Which companies on this list are the most interesting for you and why? 🫡

Explanation RSI:

The Relative Strength Index (RSI) is a technical indicator designed to measure the strength or weakness and direction of an asset. It was developed by Welles Wilder in 1978 and has since become one of the most widely used indicators in technical analysis.

The RSI is calculated by comparing the price fluctuations of an underlying asset over time. It is then converted into an index value from 0 to 100. A value above 70 is interpreted as "overbought" and a value below 30 as "oversold".

It is recommended to calculate the RSI with a period of 14 periods. However, some traders also experiment with other time periods. The RSI is an extremely flexible indicator and can be applied to different time periods and assets.

The RSI offers traders two types of signals:

A buy signal and a sell signal. A buy signal is generated when the RSI falls below a certain threshold, usually 30, which is considered oversold and signals that the price is likely to recover in the near future.

A sell signal is generated when the RSI rises above a certain threshold, usually 70, which is considered overbought and signals that the price is likely to correct in the near future.

However, the RSI alone is not sufficient to make informed trading decisions. Rather, it should be used in conjunction with other indicators and analysis methods to gain a more comprehensive understanding of market conditions.

It should also be noted that the RSI, like any other indicator, is prone to error and is not always perfect. For example, if the RSI is stuck in overbought or oversold territory for a long time, this may indicate a trend continuation and not necessarily an impending correction.

Overall, the RSI is a valuable indicator that can help traders assess the trend strength or weakness of an asset and identify potential reversal points.

However, the RSI should be used in conjunction with other indicators and analysis methods to gain a more comprehensive understanding of market conditions. It is also important to be aware of potential sources of error and to interpret RSI signals accordingly in order to make successful investment decisions.

There are numerous other indicators that can help traders determine the strength or weakness of an asset.

Some of the most popular alternatives to the RSI are:

The Moving Average Convergence Divergence (MACD)This indicator measures the divergence between two moving averages and is often used to identify trends and turning points.

The Stochastic IndicatorThis indicator measures the relationship between the closing price of an asset and its price range over a certain period of time and makes it easier to identify an overbought or oversold market.

The Williams %R indicatorSimilar to the RSI, Williams %R measures the ratio of the highest and lowest price of an asset within a given time period. There are differences in the calculation of the RSI and Williams %R, but the results are similar.

The On-Balance Volume (OBV)This indicator measures the trading volume in relation to the price movements of an asset and is used to identify potential buy or sell signals.

The Money Flow Index (MFI)This indicator is similar to the RSI, but also includes trading volume in the calculation and helps to identify overbought and oversold market conditions.

Each indicator has its own strengths and weaknesses, and none of them are perfect. It is best to use multiple indicators to gain a more comprehensive understanding of market conditions and compare the results with other analysis methods and charting indicators.

https://de.investing.com/academy/trading/rsi-indikator-erklaerung/

@TomTurboInvest
@Multibagger what's in it for you? 😄

28 Commenti

Jakob C.@Creutzfeldt_Jakob

I also bought Novo yesterday. I am keeping an eye on Fiserv and Chipotle.

•

BamBamInvest@BamBamInvest

@Creutzfeldt_Jakob yes, some of them are interesting, even purely as a game.

•

Jakob C.@Creutzfeldt_Jakob

@BamBamInvest I actually find Chipotle quite interesting in terms of the story, I also had it in my portfolio for a while. In my view, there is still enormous potential for expansion and growth here. Of course, it's a difficult time at the moment, when people's pockets are being emptied elsewhere in the USA, nice-to-have consumption is the first thing to fall by the wayside.

•

BamBamInvest@BamBamInvest

@Creutzfeldt_Jakob possible, but not my sector 😄

•

Tom@Lumimyrsky

15H

@BamBamInvest monday i'm going cautiously long in fiserv

••

Brody@Brody

$CMG I am considering entering with a first tranche and starting a savings plan. The valuation has always been too high for me. Of course, the consumer climate and inflation are currently putting pressure on margins. However, the story is still intact and the company is expanding diligently.

•

BamBamInvest@BamBamInvest

@Brody is not my sector and I also find it difficult to understand the consumer behavior of Americans in this area. But if you ever wanted to get into the company, it's certainly not a bad time to accumulate ✌️

•

Jakob C.@Creutzfeldt_Jakob

@Brody I agree with you. I was already in with CMG, got in at around €1400 (before the split, so around €28 today), went up to around €3000 (around €60 now), then cashed in the profits. I was actually already convinced of the basic story back then. CMG is largely on the move in the USA and still has so much potential for expansion in Europe / Asia alone. But precisely because it is still so concentrated in the USA, I'm a bit hot to get in at the moment, despite many positive indicators (such as the RSI). I'm staying out at the moment and taking a close look at the overall situation.

•

Brody@Brody

@Creutzfeldt_Jakob I'm with you 💯. With 90% of sales in the USA, you can only speak of growth fantasy with a view to Europe/Asia. Therefore, only entry with 1/3 of the target size and savings plan on top.

•

juliana@juliana-investment

In another post below, I talked about parting with Novo. I'm just annoyed by the company and really don't see any more potential there. The whole company is based on hope. The figures are good, the company is still very well positioned, but this is not reflected in the share price. Sometimes I think the share is cursed. I don't want to have to wait 10 years to see if anything happens and before I incur further losses, I would get rid of the share and add to Microsoft, for example. How do you see novo developing over the next 5 years?

•

B. T.@Aktienhauptmeister

@juliana-investment $NOVO B has already been discussed and speculated on more times than any other share. I don't think I see much need to talk here 😂 only who wants to trade and who doesn't ✌️

•

BamBamInvest@BamBamInvest

@juliana-investment I have a good view of them and am convinced that they are still the global market leader and selling now would be the wrong decision in my opinion. The pipeline is full and the sales market is expected to increase fivefold by 2030. Research and development is continuing and patents are still valid until 2030-2032. Right now, I would rather invest in $NOVO B than in $MSFT. From a value perspective and possible sector rotation. I don't see $NOVO B purely as a biotech. as the more sensible investment. But of course I don't know your strategy, how long you want to hold etc. The dividend is also easily paid out of cash flow and I don't see it as a risk. But do what you feel comfortable with. If there comes a phase where tech doesn't feel like it's going up 5-10% every day. I would feel more comfortable with $NOVO B at the valuation level. But don't get me wrong $MSFT is a great company, I'm just looking for more growth in the tech sector ✌️

•

BamBamInvest@BamBamInvest

@Aktienhauptmeister that in addition, you just have to go through the contributions.

•

B. T.@Aktienhauptmeister

@BamBamInvest this is what it looks like ! 😁

•

Weazlyy@Weazlyy

What does RSI precisely say/mean?

•

BamBamInvest@BamBamInvest

@Weazlyy https://de.wikipedia.org/wiki/Relative_Strength_Index

https://de.investing.com/academy/trading/rsi-indikator-erklaerung/

••

Chris@Multibagger

I am more of a fundamental data and momentum trader and less of a chart technician. That's why I wouldn't touch any of these stocks at the moment. They all have such a low RSI for a reason. All of them have recently disappointed on one or more occasions. Forecasts have been missed. And I generally do not invest in such stocks because, unless there are one-off special effects, there are structural problems or poor management is at the helm. I see the former at $ZTS, $FI and $NOVO B, while $CMG has only gone downhill since the change of management. I have not looked at the other three, as their business model alone means that they are not investment cases for me.
Of course, $NOVO B, for example, could go up 15-25% again. However, I don't see the time to trade on it in the current market environment. In my opinion, $NOVO B will have a difficult time in the long term. They have a medical business with diabetes. This is huge, but also highly competitive and margins are falling rapidly.

•

BamBamInvest@BamBamInvest

@Multibagger Solid answer 😁

•

Chris@Multibagger

@BamBamInvest have made an effort.😉

•

Raketentoni@Raketentoni

I asked the AI, among other things I have a test depot which is only controlled by ChatGPT.

📊 1. Novo Nordisk (NVO)

RSI: approx. 28 → clearly oversold

Chart: Strong setback after figures & price pressure due to GLP-1 price debate.

Fundamental: Sales +30%, net margin 45%, valuation (P/E ~32) moderate for the growth.

Conclusion: Strong in the long term, technically weakened in the short term. → Hold / entry possible on weakness (interesting below DKK 300).

Zoetis Inc (ZTS) 2.

RSI: ~33

Chart: Consolidation after weak Q3 results.

Fundamental: Stable veterinary division, sales growth +7%, operating margin ~37%.

Conclusion: Quality stock, hardly any debt. → Good time to gradually enter as soon as RSI stabilizes (>35).

🌯 3. Chipotle Mexican Grill (CMG)

RSI: ~27 → oversold

Chart: fell sharply after profit-taking in the US gastronomy sector.

Fundamental: Very profitable (margin ~14%), strong growth, but expensive (P/E ratio > 45).

Conclusion: Technically favorable in the short term, but risky in the long term due to valuation. → Only small position or via ETF exposure (e.g. momentum ETF).

🛰️ 4. Garmin Ltd (GRMN)

RSI: ~29

Chart: Sell-off after tech consolidation.

Fundamental: Strong balance sheet, no debt, dividend yield ~2.6%.

Conclusion: Technically oversold, fundamentally solid. → Good buy candidate in the dividend/tech segment.

💳 5. Fiserv Inc (FI)

RSI: ~32

Chart: sideways range after earnings, slightly under pressure due to bank sentiment.

Fundamental: Good cash flow, strong in payment processing, margins ~30%.

Conclusion: undervalued compared to competitors (e.g. Mastercard). → Solid value for long-term holding.

📞 6. Telefónica S.A. (TEF)

RSI: ~28

Chart: Weak for years, slightly susceptible to recovery at EUR 3.5-4.

Fundamental: High debt, but 6-7% dividend yield.

Conclusion: Pure dividend stock, no growth. → Only as an income position with a small share.

🥤 7. Celsius Holdings Inc (CELH)

RSI: ~30

Chart: fell sharply after quarterly figures (sales +30%, margin down).

Fundamental: Extremely high growth, but heavily overvalued (P/E ratio > 50).

Conclusion: Technically oversold, momentum value. → Short-term rebound possible, but not a defensive value.

•

Brody@Brody

@Raketentoni A nice example of chatbots randomly taking any historical key figures and company reports and fantasizing if you don't direct them.

•

Raketentoni@Raketentoni

23H

@Brody yup, I agree with you. It was just a try. Although I have to say the portfolio *real money* which I only keep on decisions of the AI is up 35% this year 🤷 but don't worry I do my own 😂

•

Brody@Brody

23H

@Raketentoni all good. I also didn't assume that you had put your life in the hands of Gemini and ChatGPT 😃
And I think playing an AI depot on the side is a cool project. Above all, 35% is quite something. Are you doing this via Robo Advisor or are you actively trading?

••

Raketentoni@Raketentoni

23H

No, I have set up chatgpt so that I get updates on the companies every morning and he gives me an assessment of what I should do. He runs a core - satellite strategy with 2 Etf, 5 dividend stocks, 3 growth satellites and 2 speculations 😬 I think I'll make a post in the days what he has done since 1.1.25 with the positions. He clearly says where is resistance, where to enter aggressively etc. It's not play money, but hey he's made 13.5k so far this year from 10k at the start.

•

Kate🦋@Iwamoto

19H

Marcus Koch has bought Chipotle. I bought Novo.
If this continues, Novo will soon be my biggest position.
(Memo to myself: Stop buying the dip!) 🤪

•

BamBamInvest@BamBamInvest

19H

@Iwamoto yes, but the cook is only ever in there for a short time. I think there will be a bounce at $NOVO B at the beginning of next week. Now that $PFIZER is buying $MTSR at a high price and $NOVO B has withdrawn from the bidding war, they are not spending 10 billion, which would not have been good in the current situation. Let's see buybacks then also possible, there are a lot of rumors ☺️

•

Kate🦋@Iwamoto

19H

@BamBamInvest It will definitely be exciting. Although Novo currently has the lowest valuation for 10 years, it has also lost a lot of market share to Eli Lilly. Incidentally, I am also invested in Pfizer. 🙈

•

BamBamInvest@BamBamInvest

18H

@Iwamoto Yes, but $LLY cannot and will not be able to serve all markets and existing customers who tolerate a product well will not switch so quickly. I'm really curious to see how things will continue with oral products. Easier to consume, easier storage, simpler logistics and therefore lower costs. If $NOVO B gets this approved now and is on the market before $LLY, they'll have to get on with it. I think there is enough room for both and yes $LLY also has a P/E of 40 I believe. Yes they are growing strongly, but I prefer $NOVO B ☺️ at the moment

•